Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study
Objective: to compare the efficacy and toxicity of aflibercept and bevacizumab in combination with fOLfIRI in secondline therapy for patients with metastatic colon cancer.Materials and methods. we performed a retrospective analysis of data on patients with metastatic colon cancer treated in 9 clinic...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
“ABV-press” Publishing house”, LLC
2022-03-01
|
| Series: | Тазовая хирургия и онкология |
| Subjects: | |
| Online Access: | https://ok.abvpress.ru/jour/article/view/518 |
| _version_ | 1797757028663296000 |
|---|---|
| author | M. Yu. Fedyanin L. Yu. Vladimirova V. A. Chubenko L. A. Zagorskaya A. V. Belyaeva O. L. Fakhrutdinova S. A. Belukhin A. S. Zhabina L. V. Khalikova L. V. Bolotina R. V. Orlova F. V. Moiseenko G. Z. Mukhametshina A. I. Khasanova A. V. Belonogov Kh. S. Musaeva O. Yu. Novikova I. Yu. Stradaeva I. L. Popova S. P. Erdniev A. K. Ivanova A. V. Androsova P. S. Feoktistova E. S. Kuzmina E. V. Karabina O. V. Nekrasova O. V. Sekhina A. A. Mishchenko L. A. Mukova B. Kh. Kertiev G. I. Kosar S. N. Osodoeva A. I. Kats R. R. Malina M. A. Lyadova A. A. Tryakin S. A. Tyulandin |
| author_facet | M. Yu. Fedyanin L. Yu. Vladimirova V. A. Chubenko L. A. Zagorskaya A. V. Belyaeva O. L. Fakhrutdinova S. A. Belukhin A. S. Zhabina L. V. Khalikova L. V. Bolotina R. V. Orlova F. V. Moiseenko G. Z. Mukhametshina A. I. Khasanova A. V. Belonogov Kh. S. Musaeva O. Yu. Novikova I. Yu. Stradaeva I. L. Popova S. P. Erdniev A. K. Ivanova A. V. Androsova P. S. Feoktistova E. S. Kuzmina E. V. Karabina O. V. Nekrasova O. V. Sekhina A. A. Mishchenko L. A. Mukova B. Kh. Kertiev G. I. Kosar S. N. Osodoeva A. I. Kats R. R. Malina M. A. Lyadova A. A. Tryakin S. A. Tyulandin |
| author_sort | M. Yu. Fedyanin |
| collection | DOAJ |
| description | Objective: to compare the efficacy and toxicity of aflibercept and bevacizumab in combination with fOLfIRI in secondline therapy for patients with metastatic colon cancer.Materials and methods. we performed a retrospective analysis of data on patients with metastatic colon cancer treated in 9 clinics in the Russian federation. The inclusion criteria were as follows: metastatic or locally advanced colon cancer; treatment with bevacizumab or aflibercept plus fOLfIRI in the second-line therapy. The primary outcome measure was progression-free survival (PfS). Secondary outcome measures included objective response rate and incidence of adverse events.Results. A total of 271 patients with metastatic colon cancer who received second-line therapy with bevacizumab (n = 81) or aflibercept (n = 190) between 2014 and 2018 were selected for this study. Study groups were matched for main prognostic signs. The objective response rate was 18.1 % in the bevacizumab group and 20.5 % in the aflibercept group (p = 0.7). The median PfS was 5 months (95 % confidence interval 3.8–6.1) in the aflibercept group and 7 months (95 % confidence interval 0.81–2.1) in the bevacizumab group (hazard ratio 1.4; 95 % confidence interval 0.99–2.1; p = 0.04). multivariate regression analysis demonstrated that the type of the targeted drug independently had no effect on PfS (hazard ratio 1.3; 95 % confidence interval 0.9–1.9; p = 0.2). we observed no statistically significant differences in the incidence of complications of any grades between the groups (58 % vs 72 %, p = 0.1). Patients receiving aflibercept were more likely to develop grade III–Iv arterial hypertension (2 % vs 9.5 %) and diarrhea (0 % vs 5.4 %), whereas thrombotic complications were more common in the bevacizumab group (10 % vs 1.8 %).Conclusion. we observed no significant differences in objective response rate and PfS between patients with metastatic colon cancer receiving bevacizumab or aflibercept in combination with fOLfIRI as second-line therapy. The toxicity profiles were different. Our findings can be used for choosing an optimal targeted drug for second-line treatment. |
| first_indexed | 2024-03-12T18:10:08Z |
| format | Article |
| id | doaj.art-2d03f1018a45430f833cbda769ac5776 |
| institution | Directory Open Access Journal |
| issn | 2686-9594 |
| language | Russian |
| last_indexed | 2024-03-12T18:10:08Z |
| publishDate | 2022-03-01 |
| publisher | “ABV-press” Publishing house”, LLC |
| record_format | Article |
| series | Тазовая хирургия и онкология |
| spelling | doaj.art-2d03f1018a45430f833cbda769ac57762023-08-02T09:16:27Zrus“ABV-press” Publishing house”, LLCТазовая хирургия и онкология2686-95942022-03-01113-4111710.17650/2686-9594-2021-11-3-4-11-17371Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter studyM. Yu. Fedyanin0L. Yu. Vladimirova1V. A. Chubenko2L. A. Zagorskaya3A. V. Belyaeva4O. L. Fakhrutdinova5S. A. Belukhin6A. S. Zhabina7L. V. Khalikova8L. V. Bolotina9R. V. Orlova10F. V. Moiseenko11G. Z. Mukhametshina12A. I. Khasanova13A. V. Belonogov14Kh. S. Musaeva15O. Yu. Novikova16I. Yu. Stradaeva17I. L. Popova18S. P. Erdniev19A. K. Ivanova20A. V. Androsova21P. S. Feoktistova22E. S. Kuzmina23E. V. Karabina24O. V. Nekrasova25O. V. Sekhina26A. A. Mishchenko27L. A. Mukova28B. Kh. Kertiev29G. I. Kosar30S. N. Osodoeva31A. I. Kats32R. R. Malina33M. A. Lyadova34A. A. Tryakin35S. A. Tyulandin36N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaNational Medical Research Center of Oncology, Ministry of Health of RussiaSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of RussiaSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of RussiaSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of RussiaSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of RussiaSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of RussiaSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of RussiaSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of RussiaP. A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of RussiaSaint Petersburg State UniversitySaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia; Saint Petersburg State UniversityRepublican Clinical Oncology Dispensary, Ministry of Health of the Republic of TatarstanRepublican Clinical Oncology Dispensary, Ministry of Health of the Republic of TatarstanMedsi Group of Companies, Clinical Hospital No. 1 «Medsi»Republican Oncology DispensaryRegional Clinical Oncology CenterMoscow Regional Oncology DispensarySaint Petersburg Clinical Oncology DispensarySaint Petersburg Clinical Oncology DispensarySaint Petersburg Clinical Oncology DispensarySaint Petersburg Clinical Oncology DispensaryNizhnevartovsk Oncology DispensarySalekhard Regional Clinical HospitalTula Regional Oncology DispensaryMulticare Medical Center “Medical City”Oncology Dispensary No. 5, Moscow Healthcare DepartmentPrimorsky Regional Oncology DispensaryOncology Dispensary, Ministry of Health of Kabardino-Balkar RepublicOncology Dispensary, Ministry of Health of Kabardino-Balkar RepublicOncology DispensaryBuryat Republican Oncology DispensaryOncology DispensaryOncology DispensaryCity Clinical Oncology Hospital No. 1 Moscow Healthcare DepartmentN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaObjective: to compare the efficacy and toxicity of aflibercept and bevacizumab in combination with fOLfIRI in secondline therapy for patients with metastatic colon cancer.Materials and methods. we performed a retrospective analysis of data on patients with metastatic colon cancer treated in 9 clinics in the Russian federation. The inclusion criteria were as follows: metastatic or locally advanced colon cancer; treatment with bevacizumab or aflibercept plus fOLfIRI in the second-line therapy. The primary outcome measure was progression-free survival (PfS). Secondary outcome measures included objective response rate and incidence of adverse events.Results. A total of 271 patients with metastatic colon cancer who received second-line therapy with bevacizumab (n = 81) or aflibercept (n = 190) between 2014 and 2018 were selected for this study. Study groups were matched for main prognostic signs. The objective response rate was 18.1 % in the bevacizumab group and 20.5 % in the aflibercept group (p = 0.7). The median PfS was 5 months (95 % confidence interval 3.8–6.1) in the aflibercept group and 7 months (95 % confidence interval 0.81–2.1) in the bevacizumab group (hazard ratio 1.4; 95 % confidence interval 0.99–2.1; p = 0.04). multivariate regression analysis demonstrated that the type of the targeted drug independently had no effect on PfS (hazard ratio 1.3; 95 % confidence interval 0.9–1.9; p = 0.2). we observed no statistically significant differences in the incidence of complications of any grades between the groups (58 % vs 72 %, p = 0.1). Patients receiving aflibercept were more likely to develop grade III–Iv arterial hypertension (2 % vs 9.5 %) and diarrhea (0 % vs 5.4 %), whereas thrombotic complications were more common in the bevacizumab group (10 % vs 1.8 %).Conclusion. we observed no significant differences in objective response rate and PfS between patients with metastatic colon cancer receiving bevacizumab or aflibercept in combination with fOLfIRI as second-line therapy. The toxicity profiles were different. Our findings can be used for choosing an optimal targeted drug for second-line treatment.https://ok.abvpress.ru/jour/article/view/518colon cancerchemotherapyafliberceptbevacizumabpopulation-based study |
| spellingShingle | M. Yu. Fedyanin L. Yu. Vladimirova V. A. Chubenko L. A. Zagorskaya A. V. Belyaeva O. L. Fakhrutdinova S. A. Belukhin A. S. Zhabina L. V. Khalikova L. V. Bolotina R. V. Orlova F. V. Moiseenko G. Z. Mukhametshina A. I. Khasanova A. V. Belonogov Kh. S. Musaeva O. Yu. Novikova I. Yu. Stradaeva I. L. Popova S. P. Erdniev A. K. Ivanova A. V. Androsova P. S. Feoktistova E. S. Kuzmina E. V. Karabina O. V. Nekrasova O. V. Sekhina A. A. Mishchenko L. A. Mukova B. Kh. Kertiev G. I. Kosar S. N. Osodoeva A. I. Kats R. R. Malina M. A. Lyadova A. A. Tryakin S. A. Tyulandin Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study Тазовая хирургия и онкология colon cancer chemotherapy aflibercept bevacizumab population-based study |
| title | Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study |
| title_full | Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study |
| title_fullStr | Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study |
| title_full_unstemmed | Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study |
| title_short | Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study |
| title_sort | efficacy and toxicity of aflibercept and bevacizumab in combination with folfiri in second line therapy for metastatic colon cancer a retrospective multicenter study |
| topic | colon cancer chemotherapy aflibercept bevacizumab population-based study |
| url | https://ok.abvpress.ru/jour/article/view/518 |
| work_keys_str_mv | AT myufedyanin efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT lyuvladimirova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT vachubenko efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT lazagorskaya efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT avbelyaeva efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT olfakhrutdinova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT sabelukhin efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT aszhabina efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT lvkhalikova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT lvbolotina efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT rvorlova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT fvmoiseenko efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT gzmukhametshina efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT aikhasanova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT avbelonogov efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT khsmusaeva efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT oyunovikova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT iyustradaeva efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT ilpopova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT sperdniev efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT akivanova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT avandrosova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT psfeoktistova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT eskuzmina efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT evkarabina efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT ovnekrasova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT ovsekhina efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT aamishchenko efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT lamukova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT bkhkertiev efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT gikosar efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT snosodoeva efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT aikats efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT rrmalina efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT malyadova efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT aatryakin efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy AT satyulandin efficacyandtoxicityofafliberceptandbevacizumabincombinationwithfolfiriinsecondlinetherapyformetastaticcoloncanceraretrospectivemulticenterstudy |